nVerses Capital’s ResMed RMD Stock Holding History

nVerses Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,164	Closed	-$486K	–	503
2026 Q1	$486K	Buy	2,164 +1,047	+94%	+$261K	0.44%	55
2025 Q4	$269K	Buy	+1,117	New	+$286K	0.6%	68
2024 Q4	–	Sell	-4,800	Closed	-$1.17M	–	704
2024 Q3	$1.17M	Buy	4,800 +3,500	+269%	+$782K	0.54%	4
2024 Q2	$249K	Buy	1,300 +1,000	+333%	+$203K	0.15%	225
2024 Q1	$59.4K	Buy	+300	New	+$55K	0.14%	253

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

nVerses Capital's RMD Position: Q2 2026 in Review

nVerses Capital sold out of ResMed (RMD) in Q2 2026, closing a stake of 2,164 shares — an estimated $486K sold.

nVerses Capital first reported a position in RMD in Q1 2024 and held it in 5 quarters. The position peaked at $1.17M in Q3 2024. 707 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

nVerses Capital reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 2,164 ResMed shares in Q2 2026, an estimated $486K.
nVerses Capital first reported a position in ResMed in Q1 2024 and held it in 5 quarters.
nVerses Capital's ResMed position peaked at $1.17M in Q3 2024.
707 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.